Market capitalization | $25.90b |
Enterprise Value | $29.15b |
PER (TTM) P/E ratio | 38.07 |
EV/FCF (TTM) EV/FCF | 24.99 |
EV/Sales (TTM) EV/Sales | 3.54 |
P/S ratio (TTM) P/S ratio | 3.15 |
P/B ratio (TTM) P/B ratio | 2.75 |
Sales growth (TTM) Sales growth | 5.29% |
Turnover (TTM) Turnover | $8.23b |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
18 Analysts have issued a ICON Plc forecast:
18 Analysts have issued a ICON Plc forecast:
Mar '24 |
+/-
%
|
||
Turnover | 8,232 8,232 |
5%
5%
|
|
Gross income | 1,846 1,846 |
9%
9%
|
|
EBITDA | 1,732 1,732 |
15%
15%
|
EBIT (operating result) EBIT | 1,100 1,100 |
20%
20%
|
Net profit | 683 683 |
34%
34%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Stephen Cutler |
Employees | 41,100 |
Founded | 1989 |
Website | www.iconplc.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.